In a new process for the prodn of an aq, pharmaceutical injection solution contg. 30-80 mol noramidopyrine-methanesulphonate sodium (I) psi 100 mol monophenyl-butazone (mofebutazone) (I), 15-30 mol ethylenediamine and a further 85-110 mol ethylenediamine or NaOH are added per 100 mol (I). The injection solutions are useful as antirheumatic agents. Addition of ethylenediamine or a combination of ethylenediamine and sodium hydroxide stabiliser the solution, presenting the formation of a ppte due to chemical reaction between (I) and (II).
展开▼